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Abstract
Background: We aimed to examine current practice of the management and secondary prevention of
intracerebral haemorrhage (ICH) in China where the disease is more common than in Western populations.
Methods: Data on baseline characteristics, management in-hospital and post-stroke, and outcome of ICH patients
are from the ChinaQUEST (QUality Evaluation of Stroke Care and Treatment) study, a multi-centre, prospective,
62 hospital registry in China during 2006-07.
Results: Nearly all ICH patients (n = 1572) received an intravenous haemodiluting agent such as mannitol (96%) or
a neuroprotectant (72%), and there was high use of intravenous traditional Chinese medicine (TCM) (42%).
Neurosurgery was undertaken in 137 (9%) patients; being overweight, having a low Glasgow Coma Scale (GCS)
score on admission, and Total Anterior Circulation Syndrome (TACS) clinical pattern on admission, were the only
baseline factors associated with this intervention in multivariate analyses. Neurosurgery was associated with nearly
three times higher risk of death/disability at 3 months post-stroke (odd ratio [OR] 2.60, p < 0.001). Continuation of
antihypertensives in-hospital and at 3 and 12 months post-stroke was reported in 732/935 (78%), 775/935 (83%),
and 752/935 (80%) living patients with hypertension, respectively.
Conclusions: The management of ICH in China is characterised by high rates of use of intravenous haemodiluting
agents, neuroprotectants, and TCM, and of antihypertensives for secondary prevention. The controversial efficacy of
these therapies, coupled with the current lack of treatments of proven benefit, is a call for action for more
outcomes based research in ICH.
Background
Intracerebral haemorrhage (ICH) is the most serious
and least treatable form of stroke, with up to 50% of
patients dying and half of survivors left with significant
disability [1]. Despite considerable research effort in
recent decades, there is still no convincing evidence of
benefit from any medical treatment, the role of surgery
remains controversial, and the chances of surviving ICH
has failed to improve in developed countries over recent
decades [1,2]. Although ICH occurs in about 10-15% of
all strokes in Western populations, it has high impact in
terms of acute and long-term medical care costs as well
as productivity loss, estimated to be US$6 billion
annually in the United States alone [3]. In China, as in
other parts of Asia, ICH accounts for up to a third of all
strokes [4], which, taken together with the very large at-
risk population, makes ICH a much more common dis-
ease in this region. Yet, there are few published studies
of the management of ICH in China, and thus limited
knowledge of how patterns of treatment more often
reflect local customs and practice rather than guideline
recommendations. Such data can serve the basis for
planning interventions to improve outcomes. In this
study, we examined the current management of ICH in
China, with a focus on medical intervention both on the * Correspondence: jwei@georgeinstitute.org.au
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apy for secondary prevention.
Methods
The ChinaQUEST (QUality Evaluation of Stroke Care
and Treatment) study used a prospective, multi-centre,
hospital-based, registry design to collect data on patients
admitted to hospital with acute stroke across a wide
range of urban sites in mainland China over a 5-month
period in 2006. The study methods and objectives have
been described in detail elsewhere [5,6]. A network of
62 hospitals selected from each of the Chinese govern-
ment’s 8 defined economic regions participated in the
study, with the following characteristics: 53 (85%) with
teaching status; 46 (74%) with >500 beds; 40 (64%) with
>500 stroke admissions per annum; 60 (97%) with neu-
rosurgical services; and neurology bed numbers ranged
from 16 to 160 (average 62 beds). Key neurology investi-
gators at each participating hospital were asked to
recruit 50-300 consecutive stroke patients (age
≥15 years) except those with subarachnoid haemorrhage
who would agree to 4 interview-based assessments at:
baseline (after admission), hospital discharge, and 3 and
12 months follow-up. Written informed consent was
obtained from all patients, or an appropriate family
member (in situations where the patient was disabled)
to participate. De-identifi e dd a t aw e r et r a n s f e r r e dt o
electronic Case Record Forms on a secure website con-
nected to a central, password-protected, database
located at The George Institute for Global Health in
Sydney, Australia. The study was approved by the ethics
committees of Peking University First Hospital (Beijing),
Ruijin Hospital (Shanghai), Prince of Wales Hospital
(Hong Kong), and The University of Sydney. Good Clin-
ical Practice guidelines in accordance with the Declara-
tion of Helsinki were used and the privacy of patients
was strictly protected.
Information on baseline sociodemographic situation
was obtained predominantly by face-to-face interviews,
in-hospital details including diagnosis of stroke subtype
were obtained through medical records and interviews
with patients or proxies, and follow-up details were
obtained primarily through telephone interviews. Base-
line information collected included patient socio-demo-
graphic characteristics, clinical features, pathological
stroke type, and history of co-morbid cardiovascular
(CV) risk factors. Diagnostic and management
approaches employed in-hospital (including neuroima-
ging, intravenous/oral medications, supportive care, and
surgery), medication use at 3 and 12 months post-
stroke, and various outcome measures of patients on
discharge and upon follow-up, were also recorded. Spe-
cific outcomes recorded included in-hospital complica-
tions (pneumonia, deep venous thrombosis, recurrent
stroke, urinary tract infection, other sepsis, pulmonary
embolus, coronary event, seizure, fall with injury, or any
other clinically significant event that prolonged hospital
stay), modified Rankin Scale [mRS] score, death, and
discharge destination.
Baseline characteristics considered in the analyses
included sociodemographic variables, medical history,
clinical and hospital features. Sociodemographic vari-
ables taken into account consisted of: age, sex, living
alone, low education (primary education only or illiter-
ate), and main lifetime occupation type. Medical history
variables investigated included: high CV risk (defined as
having ≥2 of the following self-reported co-morbidities
diagnosed pre-stroke: history of hypertension, diabetes,
hyperlipidaemia, atrial fibrillation, prior stroke, prior
transient ischaemic attack, or prior coronary artery dis-
ease [includes prior heart attack or angina]), current
cigarette smoking, regular alcohol consumption within
the 3 months prior to stroke onset and being overweight
(body mass index [BMI] ≥24 [7]). Clinical features con-
s i d e r e di n c l u d e dt i m ef r o ms y m p t o mo n s e tt oh o s p i t a l
presentation, ‘poor’ Glasgow Coma Scale (GCS) score
on admission (defined as 3-8 of a top score of 15), and
the Oxfordshire Community Stroke Project (OCSP) clin-
ical classification of stroke [8,9]. Hospital features inves-
tigated here included level, size, teaching status, and
location as either in a ‘rich’ or ‘poor’ provincial area
classified according to whether the 2006 Gross Regional
Product per capita for the province was above or below
the national average (2006 Gross Domestic Product per
capita 16 084 CNY [10] [US $2298, based on an
exchange rate of US $1 being equivalent to 7 CNY,
which is used throughout]). Hospitals were also geogra-
phically defined as being either ‘northern’ (includes the
areas of Beijing, Hebei, Heilongjiang, Henan, Inner
Mongolia, Jilin, Liaoning, Qinghai, Shaanxi, Shandong,
Tianjing, and Xinjiang) or ‘southern’ (includes the areas
of Anhui, Chongqing, Fujian, Guangdong, Guangxi,
Hong Kong, Hubei, Hunan, Jiangsu, Jiangxi, Shanghai,
Sichuan and Yunnan province).
Logistic regression analysis was used to determine
factors associated with any form of neurosurgical inter-
vention (includes open craniotomy haematoma evacua-
tion, shunt insertion, and microsurgery haematoma
evacuation) of ICH. Univariate analyses were first con-
ducted, followed by multivariate modelling adjusting for
age, sex and significantly different (p < 0.05) baseline
variables. In all models examined, hospital was also intro-
duced as a random effect to account for any clustering at
the hospital level. Multivariate logistic regression analysis
w a sa l s ou s e dt od e t e r m i n et h ee f f e c to fs u r g e r yo no u t -
come, adjusting for all potential confounders including
age, sex, marital status, living alone, low level of educa-
tion, active employment (part time or full time), annual
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on self-reported and post-stroke diagnoses, current cigar-
ette smoking, regular alcohol consumption, being over-
weight, time of presentation to hospital, poor admission
GCS, OCSP classification; in-hospital use of intravenous
steroid, neuroprotectant, hemodiluting agents and tradi-
tional Chinese medicine (TCM); and antihypertensive
use during the 3 months post-stroke. Data are reported
with odds ratios (OR) and 95% confidence intervals (CI).
All analyses were conducted using STATA 11.1 (Stata-
Corp LP, College Station, TX).
Results
In total, 13038 patients were screened for eligibility, but
6530 (50%) were excluded by investigators as the final
diagnosis was not stroke or stroke of recent onset
(30.9%), declined to participate (16.1%), rapid death
(1.5%), or other reasons (1.5%). A total of 6508 patients
were enrolled but 154 were excluded from analyses due
to uncertainty of diagnosis and missing data. Thus, we
included 6354 stroke cases of which 1572 (25%) were
due to ICH which were confirmed by computerised
tomography (CT) or magnetic resonance imaging (MRI)
with the exception of one case.
Table 1 shows that the ICH patients tended to be
middle aged, have a history of hypertension, and to pre-
sent within 6 hours of symptom onset. Of the various
management options, intravenous TCM, various neuro-
protectant agents (such as intravenous edaravone, gang-
lioside GM1, cattle encephalon glycoside and ignotin,
cinepazide, citicholine) and haemodiluting agents
including mannitol, were all in exceptionally high use
(Table 2). Table 3 shows that the most commonly used
neuroprotectant was citicholine. Among those patients
with specified neuroprotectant use (n = 809), the major-
ity (92.8%) used a single neuroprotectant, with 4 being
the maximum number of neuroprotectants used in any
1 patient. In-hospital mortality was 13% and more than
half of survivors were reported being disabled/dependent
at the time of hospital discharge.
Overall, neurosurgical intervention was undertaken in
137 (9%) patients, with as many patients receiving open
craniotomy as CT-guided microcatheter evacuation of
the haematoma of ICH. Logistic regression analysis
examining the relationship between neurosurgery and
baseline variables and outcome (Table 4) shows that
being overweight, having a poor GCS score on admis-
sion, and a large hemispheric (TACS) syndromic pattern
to the ICH, were the only baseline factors associated
with neurosurgical management in multivariate analyses.
Neurosurgery was associated with increased risk of
death/disability at 3 months post-stroke (OR 2.60; 95%
CI 1.55, 4.35) after adjusting for known potential
confounders.
Uptake of antihypertensive use in-hospital was evalu-
ated in 1104 surviving patients with complete data at all
follow-up time points. The frequency of antihypertensive
therapy in-hospital and at 3 and 12 months post-stroke
was 71%, 74% and 72%, respectively, in all patients (n =
1104); and 78%, 83%, 80%, respectively, in patients with
Table 1 Baseline characteristics of ICH patients*
All
N = 1572
Sociodemographic
Age, mean (SD), years 61.1 ± 12.9
Female 632 (40)
Living alone 77 (5)
Low education (primary only or illiterate) 820 (52)
Main lifetime occupation type
Manual work
† 850 (54)
None reported 162 (10)
Medical history
History of hypertension 1033 (66)
History of diabetes mellitus 122 (8)
History of hyperlipidaemia 143 (9)
Prior stroke 355 (23)
Prior coronary artery disease
‡ 150 (10)
Current smoker 399 (25)
Regular alcohol consumption
§ 411 (26)
Overweight
|| 637 (41)
Medication history (within one month of stroke onset)
Antihypertensive 730 (46)
Antiplatelet 215 (14)
Warfarin 2 (0.1)
Lipid lowering 36 (2)
Hypoglycaemic 88 (6)
Clinical features
Time from symptom onset to hospital presentation
Median (IQR), hours 3.5 (1.3,17.0)
<6 hours 922 (59)
Unknown 29 (2)
Transported to hospital by ambulance 663 (42)
Poor GCS score on admission
# 360 (23)
Clinical classification - TACS** 290 (18)
*Values are reported as mean ± SD, median (IQR), or number (percentage) of
subjects.
†Manual work includes construction, farming/forestry/fishing and related,
installation and related, manufacture and production, transportation and
driver occupations.
‡Coronary artery disease includes prior heart attack or angina.
§Within the 3 months prior to stroke onset.
||Defined as body mass index ≥24; percentage based on non-missing values, 1
missing value overall.
#GCS - Glasgow Coma Scale, poor score ≤8 in range 3 (low) to 15 (high,
normal); percentage based on non-missing values, 64 missing values overall.
**Oxfordshire Community Stroke Project Clinical Classification where TACS is
Total Anterior Cerebral Syndrome.
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after admission to hospital. In patients who had received
in-hospital antihypertensive treatment, the main reasons
for discontinuation at 12 months post-stroke were:
‘patient had no indication for therapy’ or ‘patient was
not hypertensive’ (38%), ‘patient did not refill prescrip-
tion’ (34%), and ‘patient refused therapy’ (18%). Inability
to pay was not reported by any patient as a reason for
therapy discontinuation.
Discussion
This study indicates that the management of ICH in
China is characterised by high rates of use of proven
antihypertensive therapy for secondary prevention but
also of high rates of non-evidence based medical thera-
pies, in particular of intravenous haemodiluting agents,
neuroprotectants and TCM in the acute phase.
Although TCMs (herbal/complementary therapies) have
a long tradition of therapeutic benefit for a wide variety
of conditions in China, and similarly for the popularity
of neuroprotectives in the targeting brain function, they
are not recommended in current national stroke guide-
lines [7]. Nevertheless, doctors trained through the Wes-
tern medical system in China are also exposed to TCM
teachings for 10-15% of their education programme
[11]. Thus, most doctors have some knowledge regard-
ing the fundamentals of TCM use and the traditional
prescriptions which typically consist of multiple herbs,
minerals and/or animal products boiled together to
make a drink. However, there is increasing availability
and subsequent use of commercially produced com-
pound TCMs in solid or injectable dosage forms, the
uses of which are not taught in medical school. More-
over, there appears to be an intrinsic belief that TCMs
are effective in the medical profession, even in acute
stroke, with 75% of doctors reporting that Chinese her-
bal products are ‘definitely beneficial’ i nas u r v e yo f
more than 1000 doctors from 247 hospitals across
China during 1993-1994 [12]. Further, while there is
still inconclusive evidence regarding the benefit of rou-
tine use of haemodiluting agents such as mannitol [13],
both national Chinese stroke guidelines and interna-
tional based guidelines (such as the latest American
Heart Association/American Stroke Association guide-
lines) advocate restricting their use to patients with
clear evidence of increased intracranial pressure [7,14].
Whether or not such extensive use of these therapies in
China can be attributable to higher rates of increased
Table 2 Management and outcome of ICH patients in-
hospital*
Investigations/treatment/outcome at discharge All
N = 1572
Investigations
Computerised tomography 1552 (99)
Magnetic resonance imaging 112 (7)
Supportive care
Allied health therapist
† 320 (20)
Traditional Chinese medicine therapist 121 (8)
Assisted feeding 326 (21)
Medical treatment
Antihypertensive therapy 1007 (64)
Intravenous traditional Chinese medicine 657 (42)
Intravenous neuroprotectant 1130 (72)
Intravenous haemodiluting agents (eg mannitol) 1511 (96)
Intravenous corticosteroids 158 (10)
In neurology ward with stroke unit 380 (24)
Neurosurgical intervention
Open craniotomy haematoma evacuation 59 (4)
Shunt insertion 2 (0.1)
Microsurgery haematoma evacuation 59 (4)
Other 17 (1)
Outcome at discharge
Experienced ≥1 in-hospital complication
‡ 378 (24)
Length of hospital stay, median (IQR) 18.0 (9.0,26.0)
Outcome (as measured by modified Rankin Scale)
0-2 560 (36)
3-5 802 (59)
6 201 (13)
Discharge destination for survivors
Home 1227 (78)
Alternate hospital 110 (7)
Other
§ 34 (2)
*Values are reported as median (IQR) or number (percentage) of subjects.
†Allied health therapist includes speech & language therapist, physiotherapist,
occupational therapist, rehabilitation professional, and social worker.
‡Complications include pneumonia, deep venous thrombosis, recurrent stroke,
urinary tract infection, other sepsis, pulmonary embolus, coronary event,
seizure, fall with injury, or any other clinically significant event that prolonged
hospital stay.
§Includes family/friends home and nursing home/institution and unknown.
Table 3 Characteristics of neuroprotectant use
Neuroprotectant n (%*)
Edaravone 95 (8.4)
Ganglioside GM1 29 (2.6)
Cattle encephalon glycoside and ignotin 112 (9.9)
Cinepazide 56 (5.0)
Citicholine 334 (29.6)
Other
† 198 (17.5)
Unspecified 321 (28.4)
*As a proportion of all patients on any neuroprotectant therapy (n = 1130);
groups are not mutually exclusive as 1 patient may be on more than 1
neuroprotectant.
†Use of agents including deproteinised calf blood extracts, adenosine
triphosphate, cerebroprotein extracts, cytidine disodium triphosphate, lysine,
piracetam, meclofenoxate, and sodium fructose diphosphate.
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medical profession also believes there are additional
pleiotropic benefits from mannitol, is unclear. It is
important to note, though, that such non-evidence
based practice also exists in the West, with the common
use of therapies such as prophylactic anticonvulsants
which also have a limited evidence base.
In regard to surgical management, those ICH patients
with more severe strokes at presentation, as evident by
poor GCS scores or TACS pattern, were more likely to
be surgical candidates, as has been shown by others
[15]. However, why overweight individuals were also
more likely to receive surgery is less readily explained.
Overall, nearly 1 in 10 (9%) patients received some form
of neurosurgical intervention, which is consistent with
the 13% reported in a Japanese registry [16], and near
the lower end of the spectrum of rates reported interna-
tionally that range from 2% in Hungary to 74% in
Lithuania [15]. The high uptake of CT-guided micro-
catheter evacuation of ICH is noteworthy, since it is a
promising technique that can be undertaken in low
resource settings without the need for neurosurgical
expertise [15]. In our study, neurosurgery was associated
with increased likelihood of poor outcome after adjust-
ing for potential confounders including initial severity,
pre-morbid dependency, CV comorbidities and medica-
tions used in the acute and post-acute phase. These
findings differ from current evidence indicating benefi-
cial effects of surgery [17] and likely reflect the interven-
tion being undertaken in more severe cases of ICH in
our study. Other factors that affect the choice and out-
come from surgery include the size and location of the
Table 4 Logistic regression analysis of factors associated with neurosurgical management of ICH
Surgical intervention Odds ratio (95% CI)
Crude n = 1572* Adjusted n = 1555
Socio-demographic factors
Age 0.98 (0.96, 0.99) 0.98 (0.96, 0.99)
Female 0.88 (0.60, 1.30) 0.84 (0.56, 1.27)
Living alone 1.49 (0.68, 3.24)
Low education (primary only or illiterate) 1.07 (0.72, 1.59)
Main lifetime occupation type
†
Manual work 1.01 (0.66, 1.55)
None reported 0.94 (0.48, 1.82)
Hospital factors
Level three vs level two category 2.77 (0.87, 8.85)
Large size (>500 beds) 1.63 (0.53, 5.00)
Teaching status 2.02 (0.49, 8.38)
Situated in a rich provincial area 1.11 (0.42, 2.90)
Situated in northern China 0.97 (0.37, 2.53)
Medical history
≥ 2 cardiovascular risk factors
‡ 0.70 (0.46, 1.07)
Current smoker 1.14 (0.74, 1.76)
Regular alcohol consumption 1.37 (0.91, 2.07)
Overweight (body mass index ≥24) 1.72 (1.17, 2.52) 1.68 (1.12, 2.51)
Clinical features
Time from symptom onset to hospital presentation
<6 hours 1.41 (0.93, 2.11)
Unknown -
§
Poor admission GCS score 4.04 (2.70, 6.04) 3.83 (2.51, 5.83)
Clinical classification - TACS 3.08 (1.84, 5.16) 2.23 (1.30, 3.83)
*Model with overweight was run on n = 1571 excluding 1 missing value, and model with severe admission GCS score was run on n = 1556 excluding 16 missing
values.
†Reference group: non-manual work including management, professional and related, service, sales/commercial, armed forces, and clerical/administration support.
‡Defined as ≥2 of the following: history of hypertension, diabetes, hyperlipidaemia, atrial fibrillation; prior stroke, prior transient ischaemic attack, and prior
coronary artery disease.
§Model cannot be run, no observations in outcome group for those whose time from symptom onset to hospital presentation is unknown.
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study.
Although the duration of hospital stay (median
18 days) for ICH patients in our study was compara-
tively longer than has been documented in other coun-
tries such as the United States, Brazil and Israel with
mean length of stays of 8-12 days [18-20], it was still
much shorter than in Japan, where a 38 day median
length of stay for ICH has been reported [21]. Similarly,
our finding of 13% in-hospital mortality was lower than
27% in the United States, 28% in Indonesia, and 28% in
Israel [19,20,22], but higher than 10% in Japan [21].
This is consistent with ICH being overall a milder dis-
ease in Asians compared to non-Asians [1], but there
are likely to be cultural differences in management such
as those involving withdrawal of life support, rehabilita-
tion, and home care, that are also relevant to influencing
both in-hospital and long-term survival. Indeed,
Christensen et al have shown that sites in China and
Singapore that participated in the Factor Seven for
Acute Hemorrhagic Stroke (FAST) trial had patients
enrolled with lower median GCS scores at the time of
randomisation and better 90 day survival compared with
patients from sites in other countries [23]. Although
comparisons are complicated by methodological differ-
ences and temporal variations in case mix and back-
ground care, the frequency of hypertension (66%) in our
study was comparable to that seen (74%) among patients
recruited within 6 hours of ICH into the pilot phase of
Intensive Blood Pressure Reduction in Acute Cerebral
Haemorrhage Trial (INTERACT), a multi-national clini-
cal trial whose study population consisted mainly of
Chinese participants; the higher frequency observed in
INTERACT likely attributable to the inclusion criteria
of having a high blood pressure level on presentation,
and the low frequency of diabetes (8%) found in our
study population was also analogous to those in INTER-
ACT (8% overall) [24].
With regards to secondary prevention of ICH, the
lowering of blood pressure is the most important ele-
m e n t ,a si nt h ep r i m a r yp r e v e n t i o no fI C H ,a n di s
recommended in both local and international guidelines
[7,14]. In this study, approximately 80% of those with a
history of hypertension (either self-reported or diag-
nosed in hospital) were taking antihypertensive treat-
ment, and reassuringly this figure remained near stable
over the 12 months of follow-up. For the small propor-
tion of patients who discontinued therapy, the majority
of the reasons were patient related either through pas-
sive non filling of prescriptions or the active refusal of
therapy. Although cost is a potential barrier to continua-
tion of therapy in this setting, an inability to pay was
not reported by any patient as a reason for discontinua-
tion. This may be attributable to the inclusion of
wealthier patients who could afford hospitalisation and
thus subsequent medications in this study, or the wide-
spread availability of inexpensive locally manufactured
antihypertensive agents such as nifedipine, nitrendipine,
hydrochlorothiazide, metoprolol, captopril, and enalapril
[25]. Thus, patient education programmes are warranted
to ensure therapy compliance and improved patient
outcomes.
We recognise that our study has several limitations.
To begin with, only consenting patients who were
admitted to participating hospitals with Departments of
Neurology were included. As these hospitals included
interested neurologist investigators based in generally
large well-resourced hospitals located principally in
major urban areas, the patterns of management that are
described herein may not be representative of what is
occurring in smaller and/or rural based hospitals. None-
theless, given the likely low resources available in such
settings, it is likely that any such bias in our study is
towards an overestimate of the patterns of care overall.
Another limitation is that specific clinical details, such
as the location, volume and mass effect of the haema-
toma in ICH, were not recorded in our study, so that
the various factors influencing the decision to undertake
neurosurgical intervention was not fully appreciated.
Nevertheless, variables related to stroke severity are to
some extent captured by the GCS scoring and TACS
classification systems. Although we did not use a vali-
dated stroke severity scale such as the National Insti-
tutes of Health Stroke Scale (NIHSS) due to its
inconsistent use in routine care, the much simpler and
widely known GCS has been shown to correlate well
with the NIHSS score (p < 0.001; correlation coefficient
= -0.730) [26]. Similarly, we elected to use the OCSP
syndromic classification system for both ischaemic
stroke and ICH to avoid logistical complexities over
gathering reliable information on haematoma topogra-
p h yt oc a t e g o r i s eI C H .W er e c o g n i s e ,t h o u g h ,t h a tt h e
OCSP system has not been validated in ICH, raising the
potential for misclassification bias. However, given that
all investigators were given the guidelines for the OCSP
classification system which they likely used in associa-
tion with findings from neuroimaging to enter the data,
it is likely that we achieved a tolerably useful classifica-
tion of ICH, albeit by location into ‘posterior’ (brain-
stem/cerebellum) versus ‘anterior’ (hemisphere), and of
the severity (TACS versus PACS/LACS) of the haemor-
rhage/haematoma.
Another factor to acknowledge is the difficulty of
assessing the agreement between the management stra-
tegies employed in the acute phase of ICH and those
specified by local guidelines, given the lack of data avail-
able on factors that would guide use of these interven-
tions. Moreover, our measures of baseline medical
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subject to survivor bias as a small proportion of the
patients with severe disease are likely to have died
before enrolment. However, self-reported medical his-
tory have been shown to correlate well with medical
records [27], and any investigation of current manage-
ment is likely to be most beneficial to those who survive
the first few hours after the onset of ICH, thus the effect
of these issues on the results are likely to be minimal.
Furthermore, the consistency of our findings to those in
neighbouring Japan provides some reassurance of the
validity of our data.
Conclusions
In summary, this study documents current acute man-
agement and uptake of secondary prevention for ICH in
China. With its massive population undergoing rapid
aging and other demographic transitions, China faces an
increasingly heavy burden of stroke across a variety of
health care settings. Despite encouraging high rates of
secondary preventative antihypertensive use in this
urban hospital network, there is still much room for
improvement with patient/physician education cam-
paigns. Furthermore, given the lack of therapies of pro-
ven benefit in ICH and the high use of therapies of
controversial efficacy, there is clear need for evaluations
to improve ICH outcomes and reduce the current heavy
reliance on non-evidence based practices in the acute
setting.
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